Menu
Not yet recruiting NCT07270211

MCG In Long QT Syndrome

Observational Atrial Fibrillation

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Magnetocardiography.
Who it may be relevant to
Registry conditions: Atrial Fibrillation. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Magnetocardiography in Long QT Syndrome: A Prospective Study of Its Clinical and Prognostic Utility

Overview

The primary objective of this observational study is to evaluate whether magnetocardiography (MCG) findings more accurately predict clinical outcomes in patients with acquired Long QT syndrome compared to ECG. The secondary objective is to assess differences in QT interval length between MCG and ECG. The primary safety objective is to characterize the safety profile of the CardiAQ MCG device.

Interventions

  • Diagnostic test Magnetocardiography
    MCG is a non-invasive, radiation-free imaging technique that detects the magnetic field generated by the electrical activity of the heart.

Primary outcome measures

  • Number of successful dofetilide loading using Magnetocardiography [Time frame: Baseline]
  • Number of successful dofetilide loading using Electrocardiogram [Time frame: Baseline]
Secondary outcome measures (2)
  • Magnetocardiography - QT interval length [Time frame: Baseline]
  • Electrocardiogram - QT interval length [Time frame: Baseline]

Eligibility criteria

Inclusion criteria

  • Age ≥ 18 years on the date of consent
  • Ability for participant to comply with study requirements
  • Written informed consent
  • Confirmed diagnosis of atrial fibrillation and receiving dofetilide for rhythm control in the inpatient setting.

Exclusion criteria

  • Pregnant or breastfeeding
  • Active thoracic metal implants (including pacemaker, insertable cardiac monitor, or internal defibrillators).
  • External electrical pads or devices (e.g. Pacer pads, ECG electrodes, heart rate patch), that must remain on patient's chest during MCG scan
  • Inability to lie down in a supine/inclined position and stay still on the examination bed
  • Clinical conditions that in the opinion of the Investigator would compromise the safety of the patient or ability to complete the protocol

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

United States · 1 center
  • Mayo Clinic in Rochester — Rochester

Identifiers

NCT: NCT07270211 · 25-008283

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗